{
  "description": "Diese ConceptMap dokumentiert die ATC-Code-Änderungen von 2023 zu 2024. Mehrere immunmodulatorische Substanzen wurden in neue Kategorien umklassifiziert, und Kombinationspräparate erhielten neue Codes.",
  "sourceCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2023",
  "_filename": "ConceptMap-mii-cm-onko-atc-transitions-2024.json",
  "package_name": "de.medizininformatikinitiative.kerndatensatz.onkologie",
  "date": "2024-12-12",
  "group": [ {
    "source": "http://fhir.de/CodeSystem/bfarm/atc",
    "target": "http://fhir.de/CodeSystem/bfarm/atc",
    "element": [ {
      "code": "L04AA34",
      "target": [ {
        "code": "L04AG06",
        "comment": "Reklassifizierung innerhalb der Immunsuppressiva",
        "display": "Alemtuzumab",
        "equivalence": "equivalent"
      } ],
      "display": "Alemtuzumab"
    }, {
      "code": "L04AA26",
      "target": [ {
        "code": "L04AG04",
        "display": "Belimumab",
        "equivalence": "equivalent"
      } ],
      "display": "Belimumab"
    }, {
      "code": "L04AA25",
      "target": [ {
        "code": "L04AJ01",
        "comment": "Reklassifizierung zu Komplement-Inhibitoren",
        "display": "Eculizumab",
        "equivalence": "equivalent"
      } ],
      "display": "Eculizumab"
    }, {
      "code": "L04AA21",
      "target": [ {
        "code": "L04AG02",
        "display": "Efalizumab",
        "equivalence": "equivalent"
      } ],
      "display": "Efalizumab"
    }, {
      "code": "L01EG02",
      "target": [ {
        "code": "L04AH02",
        "comment": "Zusätzliche Klassifizierung als Immunsuppressivum (behält auch L01EG02)",
        "display": "Everolimus",
        "equivalence": "equivalent"
      } ],
      "display": "Everolimus"
    }, {
      "code": "L04AA27",
      "target": [ {
        "code": "L04AE01",
        "comment": "Reklassifizierung zu Sphingosin-1-Phosphat-Rezeptor-Modulatoren",
        "display": "Fingolimod",
        "equivalence": "equivalent"
      } ],
      "display": "Fingolimod"
    }, {
      "code": "L04AA13",
      "target": [ {
        "code": "L04AK01",
        "display": "Leflunomid",
        "equivalence": "equivalent"
      } ],
      "display": "Leflunomid"
    }, {
      "code": "L01FX24",
      "target": [ {
        "code": "L01FX25",
        "comment": "Code-Anpassung innerhalb der bispezifischen Antikörper",
        "display": "Mosunetuzumab",
        "equivalence": "equivalent"
      } ],
      "display": "Mosunetuzumab"
    }, {
      "code": "L04AA02",
      "target": [ {
        "code": "L04AG01",
        "display": "Muromonab-CD3",
        "equivalence": "equivalent"
      } ],
      "display": "Muromonab-CD3"
    }, {
      "code": "L04AA23",
      "target": [ {
        "code": "L04AG03",
        "display": "Natalizumab",
        "equivalence": "equivalent"
      } ],
      "display": "Natalizumab"
    }, {
      "code": "L01XY03",
      "target": [ {
        "code": "L01FY02",
        "comment": "Reklassifizierung zu Kombinationen monoklonaler Antikörper",
        "display": "Nivolumab und Relatlimab",
        "equivalence": "equivalent"
      } ],
      "display": "Nivolumab und Relatlimab"
    }, {
      "code": "L01FA02",
      "target": [ {
        "code": "L04AG12",
        "comment": "Zusätzliche Klassifizierung als Immunsuppressivum (behält auch L01FA02)",
        "display": "Ofatumumab",
        "equivalence": "equivalent"
      } ],
      "display": "Ofatumumab"
    }, {
      "code": "L01XY02",
      "target": [ {
        "code": "L01FY01",
        "comment": "Reklassifizierung zu Kombinationen monoklonaler Antikörper",
        "display": "Pertuzumab und Trastuzumab",
        "equivalence": "equivalent"
      } ],
      "display": "Pertuzumab und Trastuzumab"
    }, {
      "code": "L04AA10",
      "target": [ {
        "code": "L04AH01",
        "comment": "Reklassifizierung zu mTOR-Inhibitoren (Immunsuppressiva)",
        "display": "Sirolimus",
        "equivalence": "equivalent"
      } ],
      "display": "Sirolimus"
    } ]
  } ],
  "meta": {
    "profile": [ "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-shareableconceptmap", "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-publishableconceptmap" ],
    "extension": [ {
      "url": "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-license",
      "valueCode": "CC-BY-4.0"
    }, {
      "url": "http://hl7.org/fhir/StructureDefinition/package-source",
      "extension": [ {
        "url": "packageId",
        "valueId": "de.medizininformatikinitiative.kerndatensatz.onkologie"
      }, {
        "url": "version",
        "valueString": "2027.0.0-ballot"
      }, {
        "url": "uri",
        "valueUri": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko"
      } ]
    } ]
  },
  "publisher": "Medizininformatik Initiative",
  "jurisdiction": [ {
    "coding": [ {
      "code": "DE",
      "system": "urn:iso:std:iso:3166",
      "display": "Germany"
    } ]
  } ],
  "purpose": "Migration von ATC-Codes für immunmodulatorische Substanzen und Kombinationspräparate, die 2024 umkodiert wurden.",
  "name": "MII_CM_Onko_ATC_Transitions_2024",
  "type": null,
  "experimental": "false",
  "resourceType": "ConceptMap",
  "title": "MII CM Onko ATC Code Changes 2023 to 2024",
  "package_version": "2027.0.0-ballot",
  "extension": [ {
    "url": "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability",
    "valueCode": "shareable"
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability",
    "valueCode": "publishable"
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/artifact-versionPolicy",
    "valueCodeableConcept": {
      "coding": [ {
        "code": "package",
        "system": "http://terminology.hl7.org/CodeSystem/artifact-version-policy-codes",
        "display": "Package"
      } ]
    }
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/resource-approvalDate",
    "valueDate": "2026-09-15"
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/artifact-topic",
    "valueCodeableConcept": {
      "coding": [ {
        "code": "C3262",
        "system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"
      } ]
    }
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/artifact-author",
    "valueContactDetail": {
      "telecom": [ {
        "value": "thomas.debertshaeuser@charite.de",
        "system": "email"
      } ]
    }
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/artifact-editor",
    "valueContactDetail": {
      "name": "Taskforce Core Data Set"
    }
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/artifact-reviewer",
    "valueContactDetail": {
      "name": "Interoperability Working Group",
      "telecom": [ {
        "value": "https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group",
        "system": "url"
      } ]
    }
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/artifact-reviewer",
    "valueContactDetail": {
      "name": "National Steering Committee",
      "telecom": [ {
        "value": "https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee",
        "system": "url"
      } ]
    }
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/artifact-endorser",
    "valueContactDetail": {
      "name": "Interoperability Working Group",
      "telecom": [ {
        "value": "https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group",
        "system": "url"
      } ]
    }
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/artifact-endorser",
    "valueContactDetail": {
      "name": "National Steering Committee",
      "telecom": [ {
        "value": "https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee",
        "system": "url"
      } ]
    }
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/artifact-versionAlgorithm",
    "valueCoding": {
      "code": "semver",
      "system": "http://hl7.org/fhir/version-algorithm",
      "display": "SemVer"
    }
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/resource-effectivePeriod",
    "valuePeriod": {
      "start": "2027"
    }
  } ],
  "targetCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2024",
  "status": "active",
  "id": "246b5043-e1e7-46c8-8d9e-7d7a589a745c",
  "kind": null,
  "url": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ConceptMap/mii-cm-onko-atc-transitions-2024",
  "version": "2027.0.0-ballot",
  "contact": [ {
    "name": "Medizininformatik Initiative",
    "telecom": [ {
      "value": "https://www.medizininformatik-initiative.de/",
      "system": "url"
    } ]
  } ]
}